Extending the Promise of Chimeric Antigen Receptor T-Cell Therapy Beyond Targeting CD19 Tumors

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2021 Jan 12

PMID 33434072

Authors

Natalie S Grover

Nicholas Tschernia

Gianpietro Dotti

Barbara Savoldo

Affiliations

Soon will be listed here.

References

Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y . Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide. Int J Oncol. 2012; 41(3):876-84. PMC: 3582943. DOI: 10.3892/ijo.2012.1545. View

Stojanovic A, Correia M, Cerwenka A . The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease. Front Immunol. 2018; 9:827. PMC: 5924773. DOI: 10.3389/fimmu.2018.00827. View

Scheuermann R, Racila E . CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995; 18(5-6):385-97. DOI: 10.3109/10428199509059636. View

Murad J, Graber D, Sentman C . Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies. Best Pract Res Clin Haematol. 2018; 31(2):176-183. PMC: 6428197. DOI: 10.1016/j.beha.2018.03.003. View

Hsi E, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum B . CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008; 14(9):2775-84. PMC: 4433038. DOI: 10.1158/1078-0432.CCR-07-4246. View

Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C . An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res. 1998; 58(6):1116-9. View

Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View

Strati P, Fanale M, Oki Y, Turturro F, Fayad L, Bartlett N . ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica. 2018; 104(2):e65-e67. PMC: 6355491. DOI: 10.3324/haematol.2018.199844. View

Kim M, Yu K, Kenderian S, Ruella M, Chen S, Shin T . Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 2018; 173(6):1439-1453.e19. PMC: 6003425. DOI: 10.1016/j.cell.2018.05.013. View

10.

Srivastava S, Salter A, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K . Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 2019; 35(3):489-503.e8. PMC: 6450658. DOI: 10.1016/j.ccell.2019.02.003. View

11.

Liu W, Shipp M . Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2017; 2017(1):310-316. PMC: 6142542. DOI: 10.1182/asheducation-2017.1.310. View

12.

Maciocia P, Wawrzyniecka P, Philip B, Ricciardelli I, Akarca A, Onuoha S . Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017; 23(12):1416-1423. DOI: 10.1038/nm.4444. View

13.

Greaves P, Clear A, Coutinho R, Wilson A, Matthews J, Owen A . Expression of FOXP3, CD68, and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol. 2012; 31(2):256-62. PMC: 5321049. DOI: 10.1200/JCO.2011.39.9881. View

14.

Ritchie D, Neeson P, Khot A, Peinert S, Tai T, Tainton K . Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013; 21(11):2122-9. PMC: 3831035. DOI: 10.1038/mt.2013.154. View

15.

Pont M, Hill T, Cole G, Abbott J, Kelliher J, Salter A . γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134(19):1585-1597. PMC: 6871311. DOI: 10.1182/blood.2019000050. View

16.

Litzow M, Ferrando A . How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015; 126(7):833-41. DOI: 10.1182/blood-2014-10-551895. View

17.

Ramos C, Ballard B, Zhang H, Dakhova O, Gee A, Mei Z . Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017; 127(9):3462-3471. PMC: 5669573. DOI: 10.1172/JCI94306. View

18.

Hosen N, Matsunaga Y, Hasegawa K, Matsuno H, Nakamura Y, Makita M . The activated conformation of integrin β is a novel multiple myeloma-specific target for CAR T cell therapy. Nat Med. 2017; 23(12):1436-1443. DOI: 10.1038/nm.4431. View

19.

Wang C, Wu Z, Wang Y, Guo Y, Dai H, Wang X . Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. Clin Cancer Res. 2016; 23(5):1156-1166. DOI: 10.1158/1078-0432.CCR-16-1365. View

20.

Ehninger A, Kramer M, Rollig C, Thiede C, Bornhauser M, von Bonin M . Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014; 4:e218. PMC: 4080210. DOI: 10.1038/bcj.2014.39. View